グルカゴンの機会分析と業界予測 2024-2033年

Glucagon Market

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

グルカゴン市場は2023年に3億ドルと評価され、2024年から2033年にかけて6.4%のCAGRで成長し、2033年までに6億ドルに達すると予測されています。

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

グルカゴンは、膵臓のアルファ細胞によって産生されるペプチドホルモンです。血糖値が下がりすぎると血糖値を上昇させ、体内のエネルギーバランスを維持することにより、グルコース代謝において重要な役割を果たします。このホルモンは主に肝臓に作用し、グリコーゲンの分解 (グリコーゲン分解) を促進し、非炭水化物源からのグルコースの生成 (糖新生) を刺激します。グルカゴンは血糖値を下げるインスリンに対抗して働きます。

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client’s interest
• Expanded list for Company Profiles
• Reimbursement Scenario

Glucagon Market , by Product Type Report Highlights

Aspects	Details
Market Size By 2033	USD 0.6 Billion
Growth Rate	CAGR of 6.4%
Forecast period	2024 – 2033
Report Pages	216
By Product Type	Injectable Glucagon Nasal Glucagon
By Application	Hypoglycemia Diagnostic Aid
By Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Pfizer Inc., Eli Lilly and Company., Taj Pharmaceuticals Limited, Xeris Biopharma Holdings, Inc., Zealand Pharma A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., ILS Inc, Novo Nordisk A/S, United Biotech (P) Limited

Key Market Segments

By Product Type

• Injectable Glucagon
• Nasal Glucagon

By Application

• Hypoglycemia
• Diagnostic Aid

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

○ U.S.

○ Canada

○ Mexico

• Europe

○ France

○ Germany

○ Italy

○ Spain

○ UK

○ Rest of Europe

• Asia-Pacific

○ China

○ Japan

○ India

○ South Korea

○ Australia

○ Rest of Asia-Pacific

• LAMEA

○ Brazil

○ South Africa

○ Saudi Arabia

○ Rest of LAMEA

• Key Market Players

○ Novo Nordisk A/S

○ Fresenius SE & Co. KGaA

○ Amphastar Pharmaceuticals, Inc.

○ Xeris Biopharma Holdings, Inc.

○ ILS Inc

○ United Biotech (P) Limited

○ Zealand Pharma A/S

○ Taj Pharmaceuticals Limited

○ Eli Lilly and Company.

○ Pfizer Inc.

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter’s Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

CHAPTER 4: GLUCAGON  MARKET, BY PRODUCT TYPE

4.1. Market Overview

4.1.1 Market Size and Forecast, By Product Type

4.2. Injectable Glucagon

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Nasal Glucagon

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON  MARKET, BY APPLICATION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Application

5.2. Hypoglycemia

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Diagnostic Aid

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview

6.1.1 Market Size and Forecast, By Distribution Channel

6.2. Hospital Pharmacies

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. Retail Pharmacies

6.3.1. Key Market Trends, Growth Factors and Opportunities

6.3.2. Market Size and Forecast, By Region

6.3.3. Market Share Analysis, By Country

6.4. Online Pharmacies

6.4.1. Key Market Trends, Growth Factors and Opportunities

6.4.2. Market Size and Forecast, By Region

6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON  MARKET, BY REGION

7.1. Market Overview

7.1.1 Market Size and Forecast, By Region

7.2. North America

7.2.1. Key Market Trends and Opportunities

7.2.2. Market Size and Forecast, By Product Type

7.2.3. Market Size and Forecast, By Application

7.2.4. Market Size and Forecast, By Distribution Channel

7.2.5. Market Size and Forecast, By Country

7.2.6. U.S. Glucagon  Market

7.2.6.1. Market Size and Forecast, By Product Type

7.2.6.2. Market Size and Forecast, By Application

7.2.6.3. Market Size and Forecast, By Distribution Channel

7.2.7. Canada Glucagon  Market

7.2.7.1. Market Size and Forecast, By Product Type

7.2.7.2. Market Size and Forecast, By Application

7.2.7.3. Market Size and Forecast, By Distribution Channel

7.2.8. Mexico Glucagon  Market

7.2.8.1. Market Size and Forecast, By Product Type

7.2.8.2. Market Size and Forecast, By Application

7.2.8.3. Market Size and Forecast, By Distribution Channel

7.3. Europe

7.3.1. Key Market Trends and Opportunities

7.3.2. Market Size and Forecast, By Product Type

7.3.3. Market Size and Forecast, By Application

7.3.4. Market Size and Forecast, By Distribution Channel

7.3.5. Market Size and Forecast, By Country

7.3.6. France Glucagon  Market

7.3.6.1. Market Size and Forecast, By Product Type

7.3.6.2. Market Size and Forecast, By Application

7.3.6.3. Market Size and Forecast, By Distribution Channel

7.3.7. Germany Glucagon  Market

7.3.7.1. Market Size and Forecast, By Product Type

7.3.7.2. Market Size and Forecast, By Application

7.3.7.3. Market Size and Forecast, By Distribution Channel

7.3.8. Italy Glucagon  Market

7.3.8.1. Market Size and Forecast, By Product Type

7.3.8.2. Market Size and Forecast, By Application

7.3.8.3. Market Size and Forecast, By Distribution Channel

7.3.9. Spain Glucagon  Market

7.3.9.1. Market Size and Forecast, By Product Type

7.3.9.2. Market Size and Forecast, By Application

7.3.9.3. Market Size and Forecast, By Distribution Channel

7.3.10. UK Glucagon  Market

7.3.10.1. Market Size and Forecast, By Product Type

7.3.10.2. Market Size and Forecast, By Application

7.3.10.3. Market Size and Forecast, By Distribution Channel

7.3.11. Rest Of Europe Glucagon  Market

7.3.11.1. Market Size and Forecast, By Product Type

7.3.11.2. Market Size and Forecast, By Application

7.3.11.3. Market Size and Forecast, By Distribution Channel

7.4. Asia-Pacific

7.4.1. Key Market Trends and Opportunities

7.4.2. Market Size and Forecast, By Product Type

7.4.3. Market Size and Forecast, By Application

7.4.4. Market Size and Forecast, By Distribution Channel

7.4.5. Market Size and Forecast, By Country

7.4.6. China Glucagon  Market

7.4.6.1. Market Size and Forecast, By Product Type

7.4.6.2. Market Size and Forecast, By Application

7.4.6.3. Market Size and Forecast, By Distribution Channel

7.4.7. Japan Glucagon  Market

7.4.7.1. Market Size and Forecast, By Product Type

7.4.7.2. Market Size and Forecast, By Application

7.4.7.3. Market Size and Forecast, By Distribution Channel

7.4.8. India Glucagon  Market

7.4.8.1. Market Size and Forecast, By Product Type

7.4.8.2. Market Size and Forecast, By Application

7.4.8.3. Market Size and Forecast, By Distribution Channel

7.4.9. South Korea Glucagon  Market

7.4.9.1. Market Size and Forecast, By Product Type

7.4.9.2. Market Size and Forecast, By Application

7.4.9.3. Market Size and Forecast, By Distribution Channel

7.4.10. Australia Glucagon  Market

7.4.10.1. Market Size and Forecast, By Product Type

7.4.10.2. Market Size and Forecast, By Application

7.4.10.3. Market Size and Forecast, By Distribution Channel

7.4.11. Rest of Asia-Pacific Glucagon  Market

7.4.11.1. Market Size and Forecast, By Product Type

7.4.11.2. Market Size and Forecast, By Application

7.4.11.3. Market Size and Forecast, By Distribution Channel

7.5. LAMEA

7.5.1. Key Market Trends and Opportunities

7.5.2. Market Size and Forecast, By Product Type

7.5.3. Market Size and Forecast, By Application

7.5.4. Market Size and Forecast, By Distribution Channel

7.5.5. Market Size and Forecast, By Country

7.5.6. Brazil Glucagon  Market

7.5.6.1. Market Size and Forecast, By Product Type

7.5.6.2. Market Size and Forecast, By Application

7.5.6.3. Market Size and Forecast, By Distribution Channel

7.5.7. South Africa Glucagon  Market

7.5.7.1. Market Size and Forecast, By Product Type

7.5.7.2. Market Size and Forecast, By Application

7.5.7.3. Market Size and Forecast, By Distribution Channel

7.5.8. Saudi Arabia Glucagon  Market

7.5.8.1. Market Size and Forecast, By Product Type

7.5.8.2. Market Size and Forecast, By Application

7.5.8.3. Market Size and Forecast, By Distribution Channel

7.5.9. Rest of LAMEA Glucagon  Market

7.5.9.1. Market Size and Forecast, By Product Type

7.5.9.2. Market Size and Forecast, By Application

7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top Winning Strategies

8.3. Product Mapping Of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Novo Nordisk A/S

9.1.1. Company Overview

9.1.2. Key Executives

9.1.3. Company Snapshot

9.1.4. Operating Business Segments

9.1.5. Product Portfolio

9.1.6. Business Performance

9.1.7. Key Strategic Moves and Developments

9.2. Fresenius SE And Co. KGaA

9.2.1. Company Overview

9.2.2. Key Executives

9.2.3. Company Snapshot

9.2.4. Operating Business Segments

9.2.5. Product Portfolio

9.2.6. Business Performance

9.2.7. Key Strategic Moves and Developments

9.3. Amphastar Pharmaceuticals, Inc.

9.3.1. Company Overview

9.3.2. Key Executives

9.3.3. Company Snapshot

9.3.4. Operating Business Segments

9.3.5. Product Portfolio

9.3.6. Business Performance

9.3.7. Key Strategic Moves and Developments

9.4. Xeris Biopharma Holdings, Inc.

9.4.1. Company Overview

9.4.2. Key Executives

9.4.3. Company Snapshot

9.4.4. Operating Business Segments

9.4.5. Product Portfolio

9.4.6. Business Performance

9.4.7. Key Strategic Moves and Developments

9.5. ILS Inc

9.5.1. Company Overview

9.5.2. Key Executives

9.5.3. Company Snapshot

9.5.4. Operating Business Segments

9.5.5. Product Portfolio

9.5.6. Business Performance

9.5.7. Key Strategic Moves and Developments

9.6. United Biotech (P) Limited

9.6.1. Company Overview

9.6.2. Key Executives

9.6.3. Company Snapshot

9.6.4. Operating Business Segments

9.6.5. Product Portfolio

9.6.6. Business Performance

9.6.7. Key Strategic Moves and Developments

9.7. Zealand Pharma A/S

9.7.1. Company Overview

9.7.2. Key Executives

9.7.3. Company Snapshot

9.7.4. Operating Business Segments

9.7.5. Product Portfolio

9.7.6. Business Performance

9.7.7. Key Strategic Moves and Developments

9.8. Taj Pharmaceuticals Limited

9.8.1. Company Overview

9.8.2. Key Executives

9.8.3. Company Snapshot

9.8.4. Operating Business Segments

9.8.5. Product Portfolio

9.8.6. Business Performance

9.8.7. Key Strategic Moves and Developments

9.9. Eli Lilly And Company.

9.9.1. Company Overview

9.9.2. Key Executives

9.9.3. Company Snapshot

9.9.4. Operating Business Segments

9.9.5. Product Portfolio

9.9.6. Business Performance

9.9.7. Key Strategic Moves and Developments

9.10. Pfizer Inc.

9.10.1. Company Overview

9.10.2. Key Executives

9.10.3. Company Snapshot

9.10.4. Operating Business Segments

9.10.5. Product Portfolio

9.10.6. Business Performance

9.10.7. Key Strategic Moves and Developments

LIST OF TABLES

TABLE 1. GLOBAL GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 2. GLUCAGON  MARKET FOR INJEC

TABLE GLUCAGON, BY REGION, 2024 – 2033 ($BILLION)

TABLE 3. GLUCAGON  MARKET FOR NASAL GLUCAGON, BY REGION, 2024 – 2033 ($BILLION)

TABLE 4. GLOBAL GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 5. GLUCAGON  MARKET FOR HYPOGLYCEMIA, BY REGION, 2024 – 2033 ($BILLION)

TABLE 6. GLUCAGON  MARKET FOR DIAGNOSTIC AID, BY REGION, 2024 – 2033 ($BILLION)

TABLE 7. GLOBAL GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 8. GLUCAGON  MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 – 2033 ($BILLION)

TABLE 9. GLUCAGON  MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 – 2033 ($BILLION)

TABLE 10. GLUCAGON  MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 – 2033 ($BILLION)

TABLE 11. GLUCAGON  MARKET, BY REGION, 2024 – 2033 ($BILLION)

TABLE 12. NORTH AMERICA GLUCAGON  MARKET, BY COUNTRY, 2024 – 2033 ($BILLION)

TABLE 13. NORTH AMERICA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 14. NORTH AMERICA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 15. NORTH AMERICA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 16. U.S. GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 17. U.S. GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 18. U.S. GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 19. CANADA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 20. CANADA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 21. CANADA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 22. MEXICO GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 23. MEXICO GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 24. MEXICO GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 25. EUROPE GLUCAGON  MARKET, BY COUNTRY, 2024 – 2033 ($BILLION)

TABLE 26. EUROPE GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 27. EUROPE GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 28. EUROPE GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 29. FRANCE GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 30. FRANCE GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 31. FRANCE GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 32. GERMANY GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 33. GERMANY GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 34. GERMANY GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 35. ITALY GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 36. ITALY GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 37. ITALY GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 38. SPAIN GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 39. SPAIN GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 40. SPAIN GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 41. UK GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 42. UK GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 43. UK GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 44. REST OF EUROPE GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 45. REST OF EUROPE GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 46. REST OF EUROPE GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 47. ASIA-PACIFIC GLUCAGON  MARKET, BY COUNTRY, 2024 – 2033 ($BILLION)

TABLE 48. ASIA-PACIFIC GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 49. ASIA-PACIFIC GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 50. ASIA-PACIFIC GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 51. CHINA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 52. CHINA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 53. CHINA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 54. JAPAN GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 55. JAPAN GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 56. JAPAN GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 57. INDIA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 58. INDIA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 59. INDIA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 60. SOUTH KOREA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 61. SOUTH KOREA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 62. SOUTH KOREA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 63. AUSTRALIA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 64. AUSTRALIA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 65. AUSTRALIA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 66. REST OF ASIA-PACIFIC GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 67. REST OF ASIA-PACIFIC GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 68. REST OF ASIA-PACIFIC GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 69. LAMEA GLUCAGON  MARKET, BY COUNTRY, 2024 – 2033 ($BILLION)

TABLE 70. LAMEA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 71. LAMEA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 72. LAMEA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 73. BRAZIL GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 74. BRAZIL GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 75. BRAZIL GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 76. SOUTH AFRICA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 77. SOUTH AFRICA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 78. SOUTH AFRICA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 79. SAUDI ARABIA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 80. SAUDI ARABIA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 81. SAUDI ARABIA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 82. REST OF LAMEA GLUCAGON  MARKET, BY PRODUCT TYPE, 2024 – 2033 ($BILLION)

TABLE 83. REST OF LAMEA GLUCAGON  MARKET, BY APPLICATION, 2024 – 2033 ($BILLION)

TABLE 84. REST OF LAMEA GLUCAGON  MARKET, BY DISTRIBUTION CHANNEL, 2024 – 2033 ($BILLION)

TABLE 85. NOVO NORDISK A/S: KEY EXECUTIVES

TABLE 86. NOVO NORDISK A/S: COMPANY SNAPSHOT

TABLE 87. NOVO NORDISK A/S: OPERATING SEGMENTS

TABLE 88. NOVO NORDISK A/S: PRODUCT PORTFOLIO

TABLE 89. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 90. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES

TABLE 91. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT

TABLE 92. FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS

TABLE 93. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO

TABLE 94. FRESENIUS SE AND CO. KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 95. AMPHASTAR PHARMACEUTICALS, INC.: KEY EXECUTIVES

TABLE 96. AMPHASTAR PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 97. AMPHASTAR PHARMACEUTICALS, INC.: OPERATING SEGMENTS

TABLE 98. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 99. AMPHASTAR PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 100. XERIS BIOPHARMA HOLDINGS, INC.: KEY EXECUTIVES

TABLE 101. XERIS BIOPHARMA HOLDINGS, INC.: COMPANY SNAPSHOT

TABLE 102. XERIS BIOPHARMA HOLDINGS, INC.: OPERATING SEGMENTS

TABLE 103. XERIS BIOPHARMA HOLDINGS, INC.: PRODUCT PORTFOLIO

TABLE 104. XERIS BIOPHARMA HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 105. ILS INC: KEY EXECUTIVES

TABLE 106. ILS INC: COMPANY SNAPSHOT

TABLE 107. ILS INC: OPERATING SEGMENTS

TABLE 108. ILS INC: PRODUCT PORTFOLIO

TABLE 109. ILS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 110. UNITED BIOTECH (P) LIMITED: KEY EXECUTIVES

TABLE 111. UNITED BIOTECH (P) LIMITED: COMPANY SNAPSHOT

TABLE 112. UNITED BIOTECH (P) LIMITED: OPERATING SEGMENTS

TABLE 113. UNITED BIOTECH (P) LIMITED: PRODUCT PORTFOLIO

TABLE 114. UNITED BIOTECH (P) LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 115. ZEALAND PHARMA A/S: KEY EXECUTIVES

TABLE 116. ZEALAND PHARMA A/S: COMPANY SNAPSHOT

TABLE 117. ZEALAND PHARMA A/S: OPERATING SEGMENTS

TABLE 118. ZEALAND PHARMA A/S: PRODUCT PORTFOLIO

TABLE 119. ZEALAND PHARMA A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 120. TAJ PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 121. TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 122. TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS

TABLE 123. TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

TABLE 124. TAJ PHARMACEUTICALS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 125. ELI LILLY AND COMPANY.: KEY EXECUTIVES

TABLE 126. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT

TABLE 127. ELI LILLY AND COMPANY.: OPERATING SEGMENTS

TABLE 128. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO

TABLE 129. ELI LILLY AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 130. PFIZER INC.: KEY EXECUTIVES

TABLE 131. PFIZER INC.: COMPANY SNAPSHOT

TABLE 132. PFIZER INC.: OPERATING SEGMENTS

TABLE 133. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 134. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL GLUCAGON  MARKET, 2024 – 2033

FIGURE 2. SEGMENTATION OF GLUCAGON  MARKET, 2024 – 2033

FIGURE 3. TOP INVESTMENT POCKET IN GLUCAGON  MARKET

FIGURE 4. MODERATE BARGAINING POWER OF BUYERS

FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 6. MODERATE THREAT OF NEW ENTRANTS

FIGURE 7. LOW THREAT OF SUBSTITUTION

FIGURE 8. HIGH COMPETITIVE RIVALRY

FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGLUCAGON  MARKET

FIGURE 10. GLOBAL GLUCAGON  MARKET SEGMENTATION, BY PRODUCT TYPE

FIGURE 11. GLUCAGON  MARKET FOR INJECTABLE GLUCAGON, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 12. GLUCAGON  MARKET FOR NASAL GLUCAGON, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 13. GLOBAL GLUCAGON  MARKET SEGMENTATION, BY APPLICATION

FIGURE 14. GLUCAGON  MARKET FOR HYPOGLYCEMIA, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 15. GLUCAGON  MARKET FOR DIAGNOSTIC AID, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 16. GLOBAL GLUCAGON  MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL

FIGURE 17. GLUCAGON  MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 18. GLUCAGON  MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 19. GLUCAGON  MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 – 2033 ($BILLION)

FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*

FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*

FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*

FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 24. COMPETITIVE DASHBOARD

FIGURE 25. COMPETITIVE HEATMAP: GLUCAGON  MARKET

FIGURE 26. TOP PLAYER POSITIONING, 2023

FIGURE 27. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)

FIGURE 28. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 29. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 30. FRESENIUS SE AND CO. KGAA: NET SALES, 2021-2023 ($BILLION)

FIGURE 31. FRESENIUS SE AND CO. KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 32. FRESENIUS SE AND CO. KGAA: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 33. AMPHASTAR PHARMACEUTICALS, INC.: NET SALES, 2021-2023 ($BILLION)

FIGURE 34. AMPHASTAR PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 35. AMPHASTAR PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 36. XERIS BIOPHARMA HOLDINGS, INC.: NET SALES, 2021-2023 ($BILLION)

FIGURE 37. XERIS BIOPHARMA HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 38. XERIS BIOPHARMA HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 39. ILS INC: NET SALES, 2021-2023 ($BILLION)

FIGURE 40. ILS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 41. ILS INC: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 42. UNITED BIOTECH (P) LIMITED: NET SALES, 2021-2023 ($BILLION)

FIGURE 43. UNITED BIOTECH (P) LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 44. UNITED BIOTECH (P) LIMITED: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 45. ZEALAND PHARMA A/S: NET SALES, 2021-2023 ($BILLION)

FIGURE 46. ZEALAND PHARMA A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 47. ZEALAND PHARMA A/S: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 48. TAJ PHARMACEUTICALS LIMITED: NET SALES, 2021-2023 ($BILLION)

FIGURE 49. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 50. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 51. ELI LILLY AND COMPANY.: NET SALES, 2021-2023 ($BILLION)

FIGURE 52. ELI LILLY AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 53. ELI LILLY AND COMPANY.: REVENUE SHARE, BY REGION, 2023 (%)

FIGURE 54. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)

FIGURE 55. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)

FIGURE 56. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)

Allied Market Research（アライドマーケットリサーチ）は広範な調査範囲と独自の360度メソドロジーで高リピート率を誇る（※）インドの調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

※Allied Market Researchでは2024年5月より価格体系を変更しました。弊社ウェブサイトでは旧価格体系で表示されているレポートについても新価格体系でのお取り扱いとなります。予めご了承ください。

その他の価格体系についてはお問い合わせください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（Business 1 User License）
    • ご提供ファイル：PDF
    • 印刷はユーザー数のみ可能です。例：シングルユーザライセンスに1名ユーザー追加いただいた場合には印刷は2回のみ可。
    • 2名以上でご利用の場合にはユーザー数×USD200の加算で最大4名までユーザーの追加が可能です。
  • エンタープライズライセンス
    • ご提供ファイル：印刷可能PDF＋Excel
  • クラウドアクセス
    • 納品後45日間のみオンラインでのご閲覧のみのライセンスです。
    • ダウンロード、印刷、内容のコピー＆ペーストは非対応です。
• 納品方法
  • Eメール
• 納期
  • レポートタイトルにより異なります。詳細はお気軽にお問い合わせください。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはAllied Market Researchの日本の販売代理店として、Allied Market Researchのレポートを取り扱っております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にSEMABIZまでご連絡ください。

※参照：Allied Market Research 公式ウェブサイト

最新調査レポート

• 環境修復市場の機会分析と業界予測 2024-2033年
• 冷凍パン生地市場の機会分析と業界予測 2024-2033年
• イベント産業市場の機会分析と業界予測 2024-2035年
• 音楽イベント市場の機会分析と業界予測 2024-2035年
• パワーエレクトロニクス市場の機会分析と業界予測 2024-2032年

Allied Market Research  出版レポート一覧